What happened with PFE today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Pfizer’s business centers on prescription medicines and vaccines. Wholesalers buy most of its prescription products; it also sells directly to healthcare providers, pharmacies and governments. McKesson, Cencora and Cardinal Health together account for most of its revenue, with McKesson the largest customer. Insurers and government health programs influence what Pfizer ultimately earns through negotiated discounts, reimbursement decisions and price controls.
Some important products earn money through partnerships rather than sales alone. Pfizer commercializes Eliquis with BMS and generally shares profits and losses equally. It develops and commercializes Comirnaty with BioNTech, sharing development costs and commercialization gross profits equally. Comirnaty requires authorization or approval in each market, and Pfizer has no rights to it in mainland China, Hong Kong, Macau or Taiwan.
Revenue is concentrated in a group of major products, including Eliquis. Their earnings depend on continued regulatory approval, insurance coverage and patent or regulatory protection against lower-priced generic and biosimilar competitors. Governments can restrict prices and access, and some government purchase contracts can be changed or ended at the buyer’s discretion. Pfizer relies on internal research, collaborations and acquired or licensed products to replace revenue lost as existing medicines lose exclusivity or market share.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Pfizer’s oncology results also depend on Astellas, its profit-sharing partner for Xtandi and Padcev, which is missing from this list.
Bristol Myers Squibb and Pfizer share profits from selling Eliquis, so demand and pricing affect both, even as their cancer medicines compete. Watch Eliquis demand, lower U.S. net prices and generic entry in certain international markets—the same forces shape Pfizer’s revenue from the drug.
BioNTech and Pfizer jointly develop and sell the COVID vaccine Comirnaty and split its commercialization gross profits equally, tying their vaccine earnings together. Watch vaccination uptake and contractual deliveries; their shared Comirnaty rights exclude mainland China, Hong Kong, Macau and Taiwan.
Merck competes for vaccine sales with Pfizer’s Prevnar family through its pneumococcal vaccines, while both companies also sell major cancer-drug portfolios.
Moderna competes directly for vaccine sales with Pfizer’s Comirnaty and Abrysvo through its COVID and RSV vaccines. Its revenue still comes largely from COVID vaccines, while RSV sales have been minimal, making its COVID-vaccine sales the more useful comparison for Pfizer.
GSK competes with Pfizer for RSV-vaccine sales: its Arexvy is a rival to Pfizer’s Abrysvo.
Novartis competes with Pfizer for hormone-receptor-positive breast-cancer treatment sales through Kisqali, a rival to Pfizer’s Ibrance.
AstraZeneca competes with Pfizer for sales in overlapping breast- and prostate-cancer treatment settings, where its Lynparza rivals Pfizer’s Talzenna.
AbbVie competes with Pfizer across several medicine sales: Rinvoq rivals Cibinqo and Xeljanz, while AbbVie’s migraine medicines compete with Pfizer’s Nurtec.
Lilly competes with Pfizer for breast-cancer and migraine medicine sales: Verzenio rivals Ibrance, and Lilly’s migraine medicines compete with Nurtec.
Alnylam’s Amvuttra competes directly with Pfizer’s Vyndaqel family for ATTR cardiomyopathy treatment sales. Watch acceptance of Amvuttra’s under-the-skin injections versus Pfizer’s pills; Alnylam identifies that difference as a competitive risk.
Johnson & Johnson competes with Pfizer for prescription-medicine sales in prostate cancer, multiple myeloma and inflammatory diseases.
Sanofi’s Dupixent competes with Pfizer’s Cibinqo for patients with atopic dermatitis, making Dupixent sales a relevant comparison for Pfizer’s business in that condition.
Amgen competes with Pfizer for inflammatory-disease and migraine medicine sales: Enbrel rivals Xeljanz, and Amgen’s migraine products compete with Nurtec.
Gilead competes with Pfizer for medicine sales in overlapping COVID-treatment and breast-cancer markets through its COVID treatment and breast-cancer medicines.
Takeda sells Adcetris outside the U.S. and Canada and pays Pfizer royalties on those sales, giving Pfizer income from Takeda’s business in those territories. Takeda also competes with Pfizer’s ulcerative-colitis therapies through Entyvio.
Teva challenges Pfizer’s branded-drug sales with generic medicines after exclusivity is lost, and also competes with Pfizer’s Nurtec through its migraine medicines.
Novartis AG earningsNVS
Novartis's report will show how Kisqali is selling in hormone-receptor-positive breast cancer, giving readers a read on its competitive pressure on Pfizer's Ibrance.
Look at Kisqali sales and growth, along with Novartis's description of demand in this treatment area. Strong, sustained sales would show that doctors and patients are taking up an alternative to Ibrance, increasing the pressure on Pfizer to retain patients; weak sales would point to less competitive pull, but would not prove Ibrance is winning patients back. This is evidence about Ibrance's competitive setting, not Pfizer's own sales.
GSK plc earningsGSK
GSK's report will show how Arexvy is selling, offering a read on demand for RSV vaccines that it competes to sell with Pfizer's Abrysvo.
Read changes in Arexvy sales alongside GSK's comments on vaccination demand. If Arexvy sales strengthen, a rival is winning more of the people seeking this type of vaccine, making the contest for Pfizer's Abrysvo tougher; if sales weaken, direct competitive pressure may be lower, but consider whether demand for the vaccine market as a whole has also softened. The report informs the competitive setting for Abrysvo; a rival's figures alone do not establish Pfizer's sales.
Alnylam Pharmaceuticals, Inc. earningsALNY
Alnylam's report will show demand for Amvuttra, a read on the competition its under-the-skin injections pose to Pfizer's oral Vyndaqel family.
Look at Alnylam's comments on Amvuttra sales and patient uptake, especially demand for its use in ATTR cardiomyopathy. Faster uptake would show that patients and prescribers are choosing an under-the-skin alternative to Vyndaqel, increasing the substitution pressure on Pfizer; slower uptake would mean less pull from this rival, but would not establish that Vyndaqel sales are rising. The question is whether treatment choices are tilting toward the competing option.
Bristol-Myers Squibb Co. earningsBMY
Bristol Myers Squibb sells Eliquis with Pfizer and shares its profits, so its report will show how demand and net-price pressure affect a revenue stream the two companies share.
Read Bristol Myers Squibb's Eliquis sales alongside changes in U.S. net prices. Steady demand with contained net-price pressure would support the business whose profits Pfizer and Bristol Myers Squibb share; weaker demand or price erosion would weigh on Pfizer's share of that business. Net price is after discounts and rebates, so list price alone is not enough.
Merck & Co., Inc. earningsMRK
Merck's report will show sales of its pneumococcal vaccines, helping readers assess competition and market demand for Pfizer's Prevnar family.
Track sales of Merck's pneumococcal vaccines and how the company explains demand. Growing sales may mean the rival is capturing more vaccination demand, increasing competition for Pfizer's Prevnar family; declining sales may ease that pressure, but could also reflect a weaker market overall. The key is to distinguish a rival taking demand from the whole vaccine market shrinking.
Takeda Pharmaceutical Company Limited earningsTAK
Takeda sells Adcetris outside the U.S. and Canada and pays Pfizer royalties on those sales, so its report will show how the business behind that income is changing.
Focus on Takeda's disclosures about Adcetris sales outside the U.S. and Canada. If sales in those territories grow, the base for the royalties Pfizer receives under the arrangement is stronger; if they fall, that income stream comes under pressure. Takeda's results from other products do not answer this question.
ABBVIE INC. earningsABBV
AbbVie's report will show Rinvoq's sales momentum, a read on the competition it brings to Pfizer's Xeljanz in overlapping inflammatory-disease treatment settings.
Look at AbbVie's reported Rinvoq sales and growth in the treatment settings where it competes with Xeljanz. Sustained strength in those overlapping inflammatory-disease uses would show a rival drawing patients and prescriptions, making demand harder for Pfizer to defend; slower growth would mean less competitive pull from Rinvoq, not proof that Xeljanz is recovering. The question is whether pressure on Pfizer's medicine is intensifying.
AstraZeneca PLC earningsAZN
AstraZeneca's report will show Lynparza sales, a read on the competition it brings to Pfizer's Talzenna in overlapping cancer-treatment settings.
Look at AstraZeneca's Lynparza sales and demand in the relevant treatment settings. Strength in breast- or prostate-cancer settings that overlap with Talzenna would mean tougher competition for Pfizer's oncology medicine; weak performance would suggest less pressure from Lynparza, but would not establish that Talzenna is growing. The conclusion is whether the rival is gaining strength, not what Pfizer's own results are.
Sanofi earningsSNY
Sanofi's report will show Dupixent's sales momentum in atopic dermatitis, a read on the competition facing Pfizer's Cibinqo.
Read Dupixent sales alongside Sanofi's comments on demand for atopic-dermatitis treatment. If sales and demand keep strengthening, a rival is attracting more patients and Pfizer's Cibinqo faces tougher competition; if momentum weakens, pressure from Dupixent may ease, but demand across the treatment market may also be changing. The report shows whether a competitor is drawing patients, not Cibinqo's own sales.
Pfizer Inc. earningsThis company
Pfizer earns mainly by selling medicines and vaccines, and this report will show whether growth in other products can offset falling COVID-product sales and support its revenue and earnings.
Read sales for Pfizer's major products alongside earnings from its Biopharma business. In particular, ask whether growth in products such as Vyndaqel, Eliquis and Prevnar offsets declines in Comirnaty and Paxlovid. If the growing products replace the lost revenue and earnings, Pfizer's portfolio is taking over; if the gap widens, the company remains weighed down by fading COVID-product sales despite growth elsewhere. U.S. discounts and rebates reduce the sales revenue Pfizer ultimately records, so distinguish units sold from net sales.
BioNTech SE earningsBNTX
BioNTech and Pfizer jointly develop and sell Comirnaty and split its commercialization gross profits, so this report will show how vaccination demand and contracted deliveries affect their shared business.
Look at BioNTech's comments on Comirnaty vaccination demand and contracted deliveries. Stronger uptake and fulfilled deliveries would support sales in markets where the partners share rights, and Pfizer's share of commercialization gross profits; weaker demand or fewer deliveries would weaken that support. The partners do not share Comirnaty rights in mainland China, Hong Kong, Macau or Taiwan, so this signal does not cover those markets.
Moderna, Inc. earningsMRNA
Moderna's report will show its COVID-vaccine sales, helping readers judge whether Pfizer's Comirnaty faces a competitive market or one with shrinking overall demand.
Read Moderna's COVID-vaccine sales and whether the company ties changes to vaccination demand. Stronger sales supported by uptake would show a market that still has demand, but also a rival pressing Pfizer's Comirnaty; falling sales alongside weaker demand could mean fewer vaccinations overall, not that Pfizer is gaining share. Separate the size of the market from shifts between competitors.
